News
DXCM
138.70
-0.56%
-0.78
May 10th Options Now Available For DexCom (DXCM)
NASDAQ · 17h ago
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
NASDAQ · 1d ago
Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)
Dexcom has an analyst consensus of Strong Buy, with a price target of $152.21. The company has a one-year high of $140.88. Wells Fargo maintained a Buy rating on the stock with a $145.00 price target. Larry Biegelsen is a 5-star analyst with an average return of 11.5%.
TipRanks · 3d ago
Dexcom Inc: Report of proposed sale of securities
Press release · 3d ago
Nasdaq 100 Movers: TTWO, MU
NASDAQ · 3d ago
S&P 500 Movers: TTWO, MU
NASDAQ · 3d ago
Stocks End Lower as Hawkish Fed Comments Push Bond Yields Higher
The S&P 500 Index closed down -0.31% on Monday. Some hawkish Fed comments pushed T-note yields higher and undercut stocks. Negative corporate news also weighed on the broader market. Take-Two Interactive Software closed down more than -6% after Grand Theft Auto VI production could miss release window. United Airlines Holdings closed down on reports of possible airline sanctions.
Barchart · 3d ago
Weekly Report: what happened at DXCM last week (0318-0322)?
Weekly Report · 4d ago
Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock
NASDAQ · 6d ago
DexCom (DXCM) Stock Sinks As Market Gains: Here's Why
NASDAQ · 03/19 22:00
TipRanks’ ‘Perfect 10’ List: Analysts Pound the Table on These Top-Scoring Stocks
TipRanks · 03/18 09:55
Weekly Report: what happened at DXCM last week (0311-0315)?
Weekly Report · 03/18 09:02
This Insider Has Just Sold Shares In DexCom
Kevin Sayer, the Executive Chairman of DexCom, Inc. Recently sold shares for US$4.0m. DexCom insiders didn't buy any shares over the last year. The company has a high insider ownership of 0.5% of the company. DexCom sold shares at an average price of US$134, but the company is growing profits. While the sale is discouraging, it's only a weak signal for DexCom.
Simply Wall St · 03/16 14:51
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
NASDAQ · 03/15 16:46
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 24.4% on an annualized basis. If an investor had bought $1000 of DXCM stock 15 years ago, it would be worth $120,465.
Benzinga · 03/14 20:30
Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare
NASDAQ · 03/14 13:02
Medical Devices ETF Hits 52-Week High: Stocks to Watch
NASDAQ · 03/13 16:38
Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek
NASDAQ · 03/13 11:56
DexCom started at outperform at RBC on diabetes total addressable market
DexCom started at outperform at RBC on diabetes total addressable market. The continuous glucose monitor manufacturer has a $165 price target. RBC says the company is poised to be among the fastest-growing large-cap MedTech companies. The company has a multi-year runway ahead.
Seeking Alpha · 03/12 16:52
DexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead, Bullish Analyst Says
DexCom Inc’s Stelo Glucose Biosensor System has been approved by the FDA as the first over-the-counter continuous glucose monitor (CGM) RBC Capital Markets initiated coverage of DexCom with an Outperform rating and price target of $165. Stelo is scheduled to launch in summer 2024.
Benzinga · 03/12 15:54
More
Webull provides a variety of real-time DXCM stock news. You can receive the latest news about Dexcom Inc through multiple platforms. This information may help you make smarter investment decisions.
About DXCM
DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.